In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Israel’s Teva Pharmaceutical Industries and France-based Medincell have announced results from the efficacy portion of the Phase III SOLARIS trial of olanzapine once-monthly long-acting injectable in schizophrenia compared to placebo. 9 May 2024
Pharmaceutical
Japan's largest drugmaker Takeda Pharmaceutical today announced a restructuring, as annual profit for the fiscal year to March 31, 2024 slid by more than half following the loss of patent protection of major sellers. 9 May 2024
Generics
Israeli drugmaker Teva Pharmaceutical Industries missed estimates relating to earnings and exceeded expected revenue levels in presenting its first-quarter financial results. 9 May 2024
Biosimilars
Accord BioPharma - the US specialty division of Intas Pharmaceuticals - has won US Food and Drug Administration (FDA) approval for Hercessi (trastuzumab-strf), a biosimilar to Roche’s (ROG: SIX) Herceptin (trastuzumab). 9 May 2024
Pharmaceutical
On Wednesday, the American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines issued a new clinical guideline for the evaluation and management of people with hypertrophic cardiomyopathy (HCM). 9 May 2024
Biotechnology
2023 marked a significant upsurge in US Food and Drug Administration (FDA) approvals, particularly for ground-breaking treatments such as cell and gene therapies. 9 May 2024
Biotechnology
Part of a growing trend in the industry, Ligand Pharmaceuticals has inked a royalty financing agreement with immunology company Agenus. 9 May 2024
Biotechnology
Sino-American biotech BeiGene has announced results for the first quarter of 2024 and business highlights, sending it shares up 3% to 138.46 renminbi. 9 May 2024
Biotechnology
New York-based biotech Regeneron Pharmaceuticals has announced highly encouraging results from a trial of its investigational gene therapy DB-OTO. 9 May 2024
Biotechnology
Today, the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to delpacibart etedesiran (AOC 1001). 8 May 2024
Pharmaceutical
The US Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting the new drug application (NDA) submitted by Lykos Therapeutics for midomafetamine (MDMA) capsules. 8 May 2024
Biotechnology
Shares of USA-based tumor drug resistance specialist Deciphera Pharmaceuticals soared 73% to $25.34 in morning trading, on the news that it has received a takeover bid. 8 May 2024
Biotechnology
mRNA specialist Moderna has shared details of a year-old collaboration with artificial intelligence leader OpenAI. 8 May 2024
Biotechnology
Leading biotech incubator Flagship Pioneering has announced its latest investment, with the launch of a viral proteome start-up, Prologue Medicines. 8 May 2024
Pharmaceutical
Chinese metabolic disease company Sciwind Biosciences has inked a deal with HK inno.N, a South Korean commercial stage drugmaker. 8 May 2024
Biotechnology
Swedish Orphan Biovitrum has announced that the European Commission (EC) has approved an indication extension for Aspaveli (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) who have hemolytic anemia. 8 May 2024
Pharmaceutical
The top management of life sciences companies is very optimistic about 2024 and 2025, with over 80% of pharmaceutical, medical technology and biotechnology executives expecting profit growth for the current year and over 90% for the coming year. 8 May 2024
Biotechnology
US pharma giant Pfizer shared some sad clinical trial news Tuesday. 8 May 2024
Biotechnology
The US Food and Drug Administration (FDA) has now said it will convene an in person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) on June 10, 2024, to discuss the Alzheimer's drug donanemab. 8 May 2024
Pharmaceutical
Final results from a three-year open-label extension study of Fintepla (fenfluramine) have been released by Belgium’s UCB. 8 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze